医院SAVR质量与TAVR术后30天及1年死亡率的相关性
按TAVR开展前医院风险调整SAVR死亡率四分位分层,发现基线SAVR死亡率越高,TAVR术后30天和1年死亡率也越高,多因素分析后趋势仍显著。
要点
- 基线SAVR风险调整死亡率较高的医院,TAVR术后30天和1年死亡率也较高。
- TAVR术后30天死亡率随SAVR死亡率四分位升高而增加(Q1 4.6%至Q4 5.6%,P<.001)。
- 多因素分析显示,与最低四分位相比,最高四分位医院TAVR 30天死亡率OR 1.23(95%CI 1.07-1.40)。
核心结论
- 基线SAVR死亡率较高的医院在启动TAVR项目后,TAVR术后短期和长期死亡率也较高。
- 心脏外科护理质量可能与医院开展新结构性心脏病项目的表现相关。
研究设计与样本
- 全国队列研究,纳入美国65岁及以上患者,使用2010年1月1日至2015年9月29日CMS Medicare Provider and Review数据。
- 以TAVR开展前医院风险调整SAVR 30天死亡率作为SAVR质量的替代指标,按四分位分层分析TAVR术后30天和1年死亡率。
主要发现
- TAVR术后30天观察死亡率随基线SAVR风险调整死亡率四分位升高而增加:Q1 4.6%(917例)、Q2 5.0%(381例)、Q3 5.1%(521例)、Q4 5.6%(800例),P<.001。
- TAVR术后1年死亡率同样随四分位升高而增加:Q1 17.0%(3359例)、Q2 17.5%(1337例)、Q3 18.2%(1852例)、Q4 18.6%(2652例),P<.001。
- 多因素分析显示,与最低四分位相比,Q3医院TAVR 30天死亡率OR 1.13(95%CI 1.02-1.26),Q4医院OR 1.23(95%CI 1.07-1.40),P=.02。
- 多因素分析显示,与最低四分位相比,Q3医院TAVR 1年死亡率HR 1.14(95%CI 1.02-1.28),Q4医院HR 1.16(95%CI 1.05-1.28),P=.02。
临床怎么用
- 评估医院开展TAVR项目时,可参考其既往SAVR风险调整死亡率作为心脏外科护理质量的潜在指标。
- 对于SAVR死亡率较高的医院,启动TAVR项目后需关注术后30天和1年死亡风险可能较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hospital outcomes for transcatheter aortic valve replacement (TAVR) may be dependent on the quality of evaluation, personnel, and procedural and postprocedural care common to patients undergoing cardiac surgery. OBJECTIVES: We sought to assess whether those hospitals with better patient outcomes for surgical aortic valve replacement (SAVR) subsequently achieved better TAVR outcomes after launching TAVR programs. DESIGN, SETTING, AND PARTICIPANTS: This national cohort included US patients 65 years and older. The analysis used the Centers for Medicare and Medicaid Services' Medicare Provider and Review data collected between January 1, 2010, and September 29, 2015. Only hospitals performing at least 1 SAVR prior to September 1, 2011, and performing at least 1 TAVR after this date were included in the analysis. Data analysis was completed from June 2018 to August 2018. INTERVENTIONS: Isolated aortic valve replacements. MAIN OUTCOMES AND MEASURES: Hospital risk-adjusted 30-day mortality for SAVR in the pre-TAVR period was used as a surrogate for SAVR quality. Thirty-day and 1-year TAVR mortality rates were examined after stratification by quartile of baseline hospital risk-adjusted SAVR mortality. RESULTS: A total of 51 924 TAVR procedures were performed in 519 hospitals, of which 19 798 were performed at hospitals in quartile 1 (the lowest risk-adjusted SAVR mortality rate), 7663 were performed in quartile 2, 10 180 were performed in quartile 3, and 14 283 were performed in quartile 4 (the highest risk-adjusted SAVR mortality rate). Observed mortality rates at 30 days consistently increased with increasing baseline hospital SAVR risk-adjusted mortality (quartile 1, 917 patients [4.6%]; quartile 2, 381 [5.0%]; quartile 3, 521 [5.1%]; quartile 4, 800 [5.6%]; P < .001). The same pattern was observed in 1-year mortality (quartile 1, 3359 [17.0%]; quartile 2, 1337 [17.5%]; quartile 3, 1852 [18.2%]; quartile 4, 2652 [18.6%]; P < .001). After multivariable analysis, compared with the lowest quartile of SAVR mortality, undergoing TAVR at a hospital with higher baseline SAVR mortality continued to be associated with higher 30-day mortality (odds ratios: quartile 2, 1.02 [95% CI, 0.87-1.21]; quartile 3, 1.13 [95% CI, 1.02-1.26]; quartile 4, 1.23 [95% CI, 1.07-1.40]; P = .02) and 1-year mortality (hazard ratios: quartile 2, 1.04 [95% CI, 0.92-1.17]; quartile 3, 1.14 [95% CI, 1.02-1.28]; quartile 4, 1.16 [95% CI, 1.05-1.28]; P = .02). CONCLUSIONS AND RELEVANCE: Hospitals with higher SAVR mortality rates also had higher short-term and long-term TAVR mortality after initiating TAVR programs. Quality of cardiac surgical care may be associated with a hospital's performance with new structural heart disease programs.
引用
- Kundi H, Popma JJ, Khabbaz KR, et al. Association of Hospital Surgical Aortic Valve Replacement Quality With 30-Day and 1-Year Mortality After Transcatheter Aortic Valve Replacement. JAMA Cardiol. 2019. PMID: 30516798. doi:10.1001/jamacardio.2018.4051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。